2021 Revenues ($USD) : $51,626,000,000
2021 R&D spend : $9,540,000,000
2021 Number of Employees : 104,323
Fiscal Year End : 12/31/2021
Leader : CEO Vas Narasimhan

The Basel, Switzerland–headquartered company anticipates sales growth of at least 4% CAGR from 2020 to 2026. In 2021, the drug Cosentyx had $4.7 billion in sales and 17% sales growth. Novartis noted that the drug Entresto (sacubitril/valsartan), a combination medication used for heart failure, grew 40% in FY2021. Entresto sales were $3.5 billion. Other leading drivers of growth include Cosentyx (secukinumab), Kesimpta (ofatumumab), Kisqali (ribociclib) and Zolgensma (onasemnogene abeparvovec-xioi). Novartis is reportedly considering selling its Sandoz subsidiary, which is one of the largest generic drug companies. In 2021, the unit drove $9.6 billion in sales. In March, Sandoz acquired the UK-based medical and drug delivery device development firm Coalesce Product Development. —BB